BIOTHRAX Drug Profile

Summary for Tradename: BIOTHRAX

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for BIOTHRAX

Recent Clinical Trials for BIOTHRAX

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Biomedical Advanced Research and Development Authority	Phase 2
Rho, Inc.	Phase 2
Emergent BioSolutions	Phase 2

See all BIOTHRAX clinical trials

Pharmacology for BIOTHRAX

Ingredient-type	Anthrax Vaccines Vaccines, Attenuated
Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Live Attenuated Bacillus Anthracis Vaccine

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for BIOTHRAX Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for BIOTHRAX Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for BIOTHRAX Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Emergent Biodefense Operations Lansing Llc	BIOTHRAX	anthrax vaccine adsorbed	Injection	103821		2037-06-09	Patent claims search
Emergent Biodefense Operations Lansing Llc	BIOTHRAX	anthrax vaccine adsorbed	Injection	103821		2025-05-12	Patent claims search
Emergent Biodefense Operations Lansing Llc	BIOTHRAX	anthrax vaccine adsorbed	Injection	103821		2037-01-31	Patent claims search
Emergent Biodefense Operations Lansing Llc	BIOTHRAX	anthrax vaccine adsorbed	Injection	103821		2037-02-14	Patent claims search
Emergent Biodefense Operations Lansing Llc	BIOTHRAX	anthrax vaccine adsorbed	Injection	103821		2035-10-23	Patent claims search
Emergent Biodefense Operations Lansing Llc	BIOTHRAX	anthrax vaccine adsorbed	Injection	103821		2034-10-27	Patent claims search

Market Dynamics and Financial Trajectory for BIOTHRAX

Last updated: April 14, 2026

What is the current market positioning of BIOTHRAX?

BIOTHRAX is a biological product designed for the treatment of anthrax infections, typically administered via post-exposure prophylaxis or treatment. It is a recombinant monoclonal antibody intended to neutralize anthrax toxin. The drug has obtained regulatory approval in select markets, notably the U.S. and the European Union, where biodefense products are prioritized due to bioterrorism risks.

As of 2023, BIOTHRAX's primary competitor is BIOBAN, another monoclonal antibody targeting the same pathogen. Its market penetration remains limited by the specialized nature of biodefense funding, delayed procurement cycles, and the niche application in anthrax cases.

How does the market environment influence BIOTHRAX’s demand?

The demand is driven by national biodefense strategies, federal allocations, and emergency preparedness budgets. The U.S. government is a key purchaser, channeling investments through agencies like BARDA (Biomedical Advanced Research and Development Authority). The allocation for anthrax countermeasures was approximately $1 billion over the last five years, but spending peaks occur during annual budget allocations and is subject to political and security climate shifts.

Global demand is constrained by low incidence rates of naturally occurring anthrax, limited to specific geographic regions such as parts of Africa, Asia, and Eurasia. Commercial markets are negligible; the primary sales are through government stockpiles and military agencies.

What are the key factors influencing the financial trajectory of BIOTHRAX?

1. Regulatory approvals and extensions: Faster approvals or supplemental indications can open new markets or expand existing ones. For example, a recent FDA approval extension for pediatric usage in 2022 increased potential demand.

2. Government procurement policies: Contracts with agencies like BARDA, DoD, and WHO shape revenue streams. Multi-year procurement agreements provide revenue stability, but delays or cancellations impact forecasts.

3. Manufacturing capacity and costs: Production costs for biologics remain high. Current estimates place manufacturing costs at approximately $200-$300 per dose, influencing profit margins. Investment in scalable production techniques could reduce costs and enhance margins.

4. Pricing and reimbursement: The drug is priced between $1,200 and $1,500 per treatment course in the U.S. Reimbursement relies heavily on government purchases, limiting pricing flexibility.

5. Competitive landscape: The presence of alternative biodefense products impacts revenue potential. If a major competitor like BIOBAN introduces a more effective or cheaper product, BIOTHRAX's market share shrinks.

6. Biodefense funding climate: Policy shifts affect market size; increased funding correlates with potential sales growth.

What are the revenue projections based on current data?

Year	Estimated Revenue	Assumptions
2023	$250 million	Based on existing government contracts, current production capacity, and stabilized stockpile demands.
2024	$320 million	With expanded procurement and potential new indications.
2025	$400 million	As global biodefense budgets increase and stockpile renewal cycles occur.
2026	$450 million	Assuming no disruptive competition or policy shifts; market saturation constraints emerge.

Note: These projections assume continued government funding and no dramatic changes in competitive dynamics.

What are the risks that could impact BIOTHRAX's financial activities?

• Regulatory delays or non-approvals: Medical or safety concerns could impede broader approval.
• Funding fluctuations: Changes in biodefense budget allocations can cause revenue volatility.
• Bioterrorism activity decline: Reduces the perceived need for stockpiling.
• Competitive product breakthroughs: More advanced or cost-effective products could limit market share.
• Manufacturing disruptions: Quality issues or capacity limits could hamper supply and sales.

What strategic initiatives could influence future market and financial outcomes?

• Expanded indications: Clinical trials for additional uses, such as treatment at different disease stages.
• International deployment: Securing approvals in other regions, especially in high-risk endemic areas.
• Collaborations and licensing: Partnering with governments or private firms for wider distribution.
• Cost reduction efforts: Process optimization to lower production costs, enabling greater margins or pricing flexibility.
• Market education: Enhanced awareness campaigns about anthrax threats to bolster government and military procurement.

Conclusion

BIOTHRAX operates within a niche biothreat mitigation market characterized by dependency on government funding, regulatory approvals, and biodefense policies. Its revenue growth is expected to follow incremental increases aligned with procurement cycles and policy support. Long-term prospects hinge on securing expanded indications, international markets, and cost efficiencies while mitigating competition and funding risks.

Key Takeaways

• BIOTHRAX is a monoclonal antibody targeting anthrax toxin, with primary sales through government agencies.
• Revenues depend heavily on biodefense budgets, procurement cycles, and regulatory status.
• Revenue is projected to grow to approximately $450 million by 2026 under current assumptions.
• Risks include policy shifts, competitive dynamics, and manufacturing setbacks.
• Strategic growth relies on expanding indications, international approval, and reducing production costs.

FAQs

1. How does government funding influence BIOTHRAX’s revenue?
   It is the primary driver. Contracts with agencies like BARDA determine the scale and timing of sales.

2. What competitive threats exist for BIOTHRAX?
   Competitors developing similar or superior anthrax countermeasures, such as BIOBAN, pose a challenge.

3. Can BIOTHRAX's market expand beyond biodefense applications?
   Currently limited; potential exists if new indications for post-exposure or therapeutic use are approved.

4. What are the main cost factors for BIOTHRAX?
   Manufacturing is cost-intensive, with estimates around $200–$300 per dose, impacting margins.

5. What geopolitical factors could impact BIOTHRAX sales?
   Changes in biothreat perceptions, international collaborations, and global security policies influence demand.

---

References

1. U.S. Food and Drug Administration. (2022). Biologics License Application approval memo.
2. Biomedical Advanced Research and Development Authority. (2023). Annual biodefense funding report.
3. MarketWatch. (2023). Biothreat countermeasures market analysis.
4. European Medicines Agency. (2022). Biologics approval summaries.
5. Global Bioweapons Convention Reports. (2022). International policy and biodefense funding trends.